Delphi Ventures

Arrow Markets operates a decentralized financial market options protocol designed to democratize returns for option market makers. By eliminating intermediaries such as brokers and clearinghouses, the platform streamlines the entire options trading process, facilitating market making, brokering, and settlement directly on its protocol. This approach allows liquidity providers to engage in hedging activities similar to those of traditional market makers while benefiting from reduced costs. The protocol employs cash settlement for all contingent claims, enhancing efficiency and accessibility in options trading.

MyShell is a decentralized and comprehensive platform for discovering, creating, and staking AI-native apps.

Builders of Citrea, Bitcoin's First ZK Rollup. The last few decades of innovation were defined by the internet. We believe Bitcoin and blockchains will shape the coming decades. We are a blockchain infrastructure company focused on Bitcoin, Ethereum, and Zero Knowledge technology.

Nous Research develops human-centric language models and simulators, focusing on AI flexibility and adaptability.

HYTOPIA is a metaverse platform that integrates social functions and offers developers a Minecraft-inspired game creation toolkit with flexible monetization.

FastLane protocol is designed to generate revenue for validators while increasing the effectiveness of algorithmic traders.

Karate Combat is a karate organization. They offer karate leagues, events, training, and tournaments. They offer tickets. If you have any queries please contact them by phone and email.

Mirage is developing the foundational AR infrastructure and artist tooling that will allow creators to create and curate their own decentralized trans digital reality that bridges our physical and digital worlds.

Skylock is a Canadian post-seed startup committed to securing the future of DeFi by proactively defending against smart-contract hacks. Recognizing the industry's need for stability, Skylock leverages cutting-edge technology to detect and block malicious transactions in real-time, protecting DeFi protocols and their users. Skylock was founded in 2022 in Ottawa, Canada.

Suberra is a company that specializes in facilitating cryptocurrency payments for businesses, aiming to enhance the user experience in this evolving financial landscape. It offers a range of services, including the acceptance of crypto payments for commerce, one-time transactions, and subscription models. Suberra's payment infrastructure is designed to enable safe and secure transactions, providing both consumers and merchants with a streamlined process for using cryptocurrencies and stablecoins. This approach not only simplifies payment acceptance for businesses but also empowers consumers to transact more freely and efficiently in their everyday purchases.

Godmode is the AI-native sales enablement tools. Helps you connect and build with genuine human relationships and proactively finds you leads based on your ideal customer profile and signals on the web.

Jito Labs is the MEV infrastructure company that develops systems to scale Solana and maximize validator rewards.

AMGI Studios is an animation technology agency that focuses on integrating animation with gaming. The company develops and produces both traditional entertainment and Web3 native properties, utilizing proprietary technology and innovations in real-time animation. By offering services in animation, art direction, and puppeteering, AMGI supports existing studio pipelines and enhances the landscape of animated content. Their approach merges artistry with technology, allowing animators to create compelling animated art efficiently.

Tatsumeeko is a Discord-first fantasy massively multiplayer online role-playing game (MMORPG).

ZGEN is a software firm that builds smart contracts on web3 applications for DeFi and DAO communities. They also involve in tobBuilding essentials for internet communities.

Voyage Finance is a company that specializes in providing decentralized loans tailored for gamers and gaming guilds within the Web3 ecosystem. Its platform is designed to facilitate financial support for users by offering in-game services and enabling the purchase of yield-generating assets. Additionally, it features a "play and repay" mechanism that allows gamers to manage their loans conveniently while engaging in their gaming activities. This approach aims to enhance the financial capabilities of gamers and guilds, making it easier for them to participate in the growing landscape of online gaming.

Pollen Mobile provides a decentralized mobile network that is built on the blockchain which is owned and operated by its users. Pollen Mobile helps to build its own mobile connectivity through a crypto-economy, enabling users to have reliable and affordable mobile connectivity.

Polemos is a global Gaming company that has developed advanced proprietary asset management solutions, non-collateralised lending solutions, proprietary learning management systems (LMS), advanced game/player data analytics solutions, and range of gaming focussed media and entertainment assets. Polemos was ideated and launched in early 2020 by five international cofounders that have investment and business interests in strategically aligned industry sectors. Commonly confused as a 'blockchain' business, Polemos delivers solutions to all traditional and emerging strategy gaming verticals. Led by renown global technology executive Richard McLaren, most well known for his roles as Managing Director of Microsoft NineMSN (APAC), Head of MoneySupermarket.com, Global Director at McKinsey and BCG, and as Managing Director of ThoughtWorks, and Hal Crawford - former Chief Editor and Publisher at Microsoft NineMSN, and Global CEO at Mediaworks, the business is expanding rapidly into a large number of globally distributed markets - not dissimilar to those markets pursued by Microsoft for its content business originally. Cofounders of Polemos include: Tom Hall - Former CEO of Playtech and Asian Logic, CEO of Sporting News (https://www.linkedin.com/in/tomhallhk/) - Tom Hall is recognised as a pioneer and one of the world’s leading experts in the field of online gaming software development, specialising in interactive gaming and is a regular key note speaker at investor forums and gaming conferences around the World. Tom is known globally for his role as Co-Founder and CEO of Asianlogic, an Asian-facing gaming group established in 2002. He also led Playtech as Group CEO and oversaw the successful floatation of the Company on the UK AIM market in 2006. Playtech was the world’s largest publicly quoted gaming software provider (UK:PTEC - USD3.5Bn+ Market Cap). Of Eurasian Hong Kong origin, Tom was responsible for overseeing global customer growth and the development of customised software solutions for the Asia Pacific marketplace. He retired in 2020 as Chairman to pursue his interests in the media sector. Previously publicly listed in the UK, ALOG was taken private in 2009 and grew to become one of the Top 10 Global online gaming companies with 2500 staff across 6 countries. Since 2014, Hall has spent most of his time building Pax Holdings Limited, a family office focussed on sports media, fintech, gaming, leisure-related real estate and asset management platform software development. As at 2020, his core focus is Pax’s digital media expansion, most recently leading the acquisition of The Sporting News, www.sportingnews.com, the digital evolution of the US's oldest sports newspaper founded in 1886. He has also recently joined the Board of Leisurerights.com, a newly formed rights management collective. Zac Rosenberg - Managing Partner at Capzed (https://www.linkedin.com/in/zac-rosenberg-079a34/) - Zac co-founded Capital Zed in January 2015. Previously was Managing Director/Head of Investment Banking from 2012 to 2015 at Canaccord Genuity (Melbourne), Managing Director/Head of Investment Banking from 2009 to 2012 at Keefe, Bruyette & Woods (Hong Kong), Managing Director/ Head of Investment Banking at Fox-Pitt, Kelton (Hong Kong) from 2005 to 2009 and Executive Director at CIBC World Markets (Hong Kong/Singapore) from 2000 to 2005 His current Board roles include Mobi2Go (New Zealand), The Influential Network (USA), Predictive Hire (Australia), Fresho (Australia), Campaign Agent (Australia), as well as several private investment companies and vehicles. Zac holds a Bachelor of Commerce from Monash University. Darren Smorgon - Managing Director of Sandbar Investments (https://www.linkedin.com/in/darren-smorgon-20214713/) - Darren is Managing Director of Sandbar Investments, a Sydney based family office with investments in private equity, equities, property and alternative investments including venture capital and crypto currency. Until 2015, Darren was a Director, member of the advisory board and partner at CHAMP Private Equity where he was responsible for portfolio companies including oOh!media, Study Group, Golding Contractors and LCR Group. Darren is currently Chairman of Hub Australia, Non Executive Director of Total Drains Group and Swift Networks, Co-Founder and Non Executive Director of Arrowpoint Capital. He is also actively involved in several philanthropic activities including as a member of the Allocations Committee of the JCA and the Chairman of Nextthink. Kevin O’Hara - Managing Director of Sentor Investments and Partner at Trivian Capital Management (https://www.linkedin.com/in/kevino23/) - Kevin has an extensive history as an investor and founder. In 2005 Kevin founded OCTIEF Group (Acquired by IHG and Tulla Private Equity) and in 2010 Kevin founded the OCTFOLIO SaaS based Enterprise Governance, Risk and Compliance Management (eGRCM) Solution (acquired by HRL and ALS Global Limited). Kevin has an MBA with a major in Digital Transformation and Business Intelligence and is currently Managing Director of Sentor Investments, Venture Partner at SDGx Climate Technology Fund, Venture Partner and IC Member at Primal Capital and IC Member at Newzone Ventures in Portugal. Scott Plowman - Managing Director of Mozaik Capital (https://www.linkedin.com/in/scottplowman/) - Scott is the Managing Director of Mozaik Capital based in Singapore, Co-Founder of Polemos.io, acting DAO Key Controller for the Polemos DAO, and Foundation Partner and Investor in Herradura Ventures. Mozaik Capital is most well known as one of the original Venture focussed Web3 investors, with multiple exits across Axie Infinity, Algorand, DFinity, STEPN, Yield Guild and Kava to name a few. In the web3 investing space, Scott is known for the establishment and management of large scale project validator and node structures, including for the Algorand protocol in 2018.. Today Scott is also actively involved at the foundation level of numerous technology companies. Scott’s background is in the establishment, administration and portfolio management for numerous large-scale funds and financial services organisations, and in high level technical/quantitative market analysis and derivatives trading.

Crypto Raiders is a highly-interactive dungeon crawler game built on the blockchain. Players have the ability to buy characters and mobs, go on missions, build teams in a virtual universe all while discovering NFTs they then own. Crypto Raiders is built on the Polygon blockchain, and all NFT loot is randomized, ensuring that the value of all discovered loot is random as well.

Crypto Unicorns is a Web3 game development and research and development studio.

MetalCore is a maker of computer games. They provide services for fighting games. They provide products that include mechs, infantry, aircraft, and vehicles.

Squads is a developer of a decentralized program that enables the establishment of better and easier decentralized autonomous groups. The company's application combines all of the key components of a decentralized autonomous organization, such as deployment, treasury, vault management, on-chain voting, and chat, into a single portal with an easy-to-use interface, allowing users to streamline daily operations using a decentralized autonomous organization structure.

Jambo is a company focused on creating an extensive on-chain mobile network, centered around its flagship product, the JamboPhone, a powerful mobile device designed for the crypto-native market. With a foundation of over 800,000 mobile nodes spanning more than 120 countries, Jambo aims to accelerate decentralization and enhance network effects for various applications, such as validators and peer-to-peer networking. The JamboApp serves as a gateway for millions of users to engage with the on-chain economy, offering innovative earning opportunities, a decentralized application (dApp) store, and a multi-chain wallet. By integrating blockchain technology into its products, Jambo empowers users to participate in gaming, cryptocurrency trading, and decentralized finance, particularly benefiting individuals in emerging markets. Central to Jambo's ecosystem is the Jambo Token, which facilitates rewards, discounts, and other incentives, positioning the company as a key player in the evolving landscape of blockchain technology.

DOOMSDAYX is a creative technology studio for web3 artists and fans, focused on redefining culture on-chain.

EnterDAO is a decentralized autonomous organization focused on developing products that facilitate new markets within the Web3 metaverse economy. It offers a cross-platform web3-enabled desktop application that serves as a centralized access point for various metaverse games. This application allows users to efficiently manage and interact with virtual land while providing seamless onboarding into different metaverse experiences. EnterDAO aims to enhance user engagement and streamline interactions within the evolving landscape of the metaverse.

Hubble is a decentralized financial protocol that allows for long-term borrowing, lending, and structured products.

Friktion Labs is a team of quantitative traders, researchers, and crypto engineers with backgrounds in commodities, treasuries, volatility products, and crypto-assets. The organization has brought on board a group of derivatives traders and market makers in Genesis Trading, Alameda Research, LedgerPrime, QCP Capital, CMS Holdings, Orthogonal Trading, and GSR.

Suberra is a company that specializes in facilitating cryptocurrency payments for businesses, aiming to enhance the user experience in this evolving financial landscape. It offers a range of services, including the acceptance of crypto payments for commerce, one-time transactions, and subscription models. Suberra's payment infrastructure is designed to enable safe and secure transactions, providing both consumers and merchants with a streamlined process for using cryptocurrencies and stablecoins. This approach not only simplifies payment acceptance for businesses but also empowers consumers to transact more freely and efficiently in their everyday purchases.

Hubble is a decentralized financial protocol that allows for long-term borrowing, lending, and structured products.

Beta Finance is a permissionless money market protocol for lending, borrowing, and short-selling crypto assets. It aims to offset crypto volatility and bring market stability. Its one-click solution enables traders without technical know-how to manage and update their short positions on any token with all relevant token information directly available on the interface to guide their decision.

LayerZero Labs is a developer of a blockchain messaging protocol that enables decentralized applications to function across multiple blockchains. The company's platform focuses on interoperability, facilitating data exchange between disparate blockchains. Unlike traditional methods that require sequential storage of all block headers, LayerZero employs an on-chain light node for validation, allowing block headers to be streamed on-demand by decentralized oracles. This innovative approach enhances speed, security, and cost-efficiency, providing clients with a low-level communication primitive necessary for cross-chain applications.

Tessera's mission is to curate the most extraordinary collective ownership experiences produced by the greatest creators, builders, and leaders. Tessera's vision is a world where anyone can have the opportunity to collectively own and govern things they value, without reliance on central gatekeepers to execute decisions and actions on their behalf.

Pontem Network is a product studio focused on creating foundational decentralized applications (dApps) for the Aptos blockchain. Among its offerings is the Pontem Wallet, a secure wallet available on major platforms such as Chrome, Firefox, iOS, and Android, enabling users to store and send tokens on Aptos. The wallet integrates with several key services, including the Liquidswap decentralized exchange, Topaz and Souffl3 NFT marketplaces, and various liquid staking and lending protocols. In addition to the wallet, Pontem Network provides tools for developers, including the Move Playground code editor, the Move IntelliJ IDE plugin, and ByteBabel, a Solidity-to-Move code translator. These products facilitate the development and testing of dApps, enhancing the functionality and interoperability of the Aptos ecosystem.

Bright Star Studios is an independent game development company located in Swatar, Malta, specializing in the creation of multiplayer online video games. The studio focuses on developing original MMO game franchises using its proprietary engine and aims to innovate the MMORPG landscape across platforms, including PC, mobile, and browsers. Its flagship title, Ember Sword, represents a modern approach to gaming, emphasizing a player-owned economy and community engagement. By promoting competitive gameplay and instant playability, Bright Star Studios seeks to foster a gaming environment that prioritizes skill and user involvement, challenging traditional business models in the industry.

Fractal is a financial technology company that provides digital assets and blockchain adoption services. They also develop tools for institutional investors to access decentralized financing.

Fully permissionless protocol for decentralized perpetual swaps

Covalent is the leading modular data infrastructure layer dedicated to solving major challenges in blockchain and AI, including verifiability, decentralized AI inference, and Long-Term Data Availability. Its large reservoir of structured, verifiable data enhances decentralized training and inference, reducing the risk of manipulated or biased AI models. Additionally, the Covalent Network's Ethereum Wayback Machine ensures secure, decentralized access to Ethereum’s transaction data. Trusted by over 3,000 leading organizations, Covalent powers AI, DeFi, GameFi, and more with unfettered access to on-chain data from over 225 blockchains. Learn about the EWM: Technical | Non-Technical For more information, check out Covalent’s: Official Website | Twitter/X | Linktree

XDEFI Wallet is a non-custodial cryptocurrency wallet that enables users to securely store, send, and swap digital assets, including NFTs, across 30 different blockchains. The wallet is designed to facilitate interaction with various decentralized finance (DeFi) protocols, making it a vital tool for users looking to engage in the growing DeFi ecosystem. With over 200,000 users, XDEFI Wallet provides a user-friendly platform that allows seamless access to decentralized marketplaces and NFT applications directly through web browsers. Its chain-agnostic capabilities and robust features position XDEFI Wallet as an essential resource for individuals participating in the evolving landscape of digital finance and asset management.

Anchor Protocol is a savings platform that provides crypto natives, fintech companies, and investors a stable, high interest rate finance. The company was founded in 2020 and is headquartered in Seoul, South Korea.

Armor develops a dynamic cover brokerage protocol for decentralized finance to serve cryptocurrency investors. Founded in 2021, Armor is a DeFi coverage aggregator that makes securing your DeFi assets against hacks as easy as possible. Ease wants to make DeFi as easy and safe as possible. They aim to cover every dollar in DeFi so that users can finally feel at ease.

Caravan Wellness specializes in corporate wellness programs and online education solutions aimed at promoting healthier lifestyles. The company offers a variety of wellness lessons, training classes, and challenges led by experts, focusing on nutrition, fitness, mindfulness, and productivity. By utilizing science-based methods and impact tracking, Caravan Wellness helps individuals and organizations cultivate better habits and enhance overall performance. Through brand partnerships and collaborations with influencers, the company aims to deliver exclusive digital content that supports employee wellness and fosters a culture of health within organizations.

LeddarTech Inc. specializes in advanced detection and ranging systems using time-of-flight measurement technology with infrared LEDs. The company offers a range of smart sensor modules, including single-element and multi-element systems tailored for various applications, such as industrial, traffic management, and smart home solutions. LeddarTech's technology is particularly focused on enhancing advanced driver assistance systems (ADAS) and autonomous driving by providing perception solutions that integrate data from various sensor types, including cameras and radar. Their flagship platform, LeddarVision™, facilitates the creation of comprehensive 3D environmental models, addressing critical challenges in environmental sensing and perception. With over 140 patents granted or pending, LeddarTech is committed to innovation in the automotive sector, serving original equipment manufacturers (OEMs) and automotive suppliers to accelerate development cycles and improve time-to-market. Founded in 2007 and based in Quebec City, Canada, the company also maintains a research and development office in Toronto.

AEGEA Medical, Inc. is a medical technology company based in Menlo Park, California, that specializes in innovative treatments for women's health. The company has developed a water vapor ablation system, known as Mara, which is designed for the in-office treatment of heavy menstrual bleeding, specifically menorrhagia. This FDA-approved technology utilizes adaptive vapor ablation to deliver safe and effective endometrial ablation in a simple procedure that takes only minutes. AEGEA Medical aims to expand treatment options for a broader range of patients while ensuring convenience and confidence for physicians performing these office-based procedures. The company was incorporated in 2007 and continues to focus on enhancing patient outcomes in women's healthcare.

AEGEA Medical, Inc. is a medical technology company based in Menlo Park, California, that specializes in innovative treatments for women's health. The company has developed a water vapor ablation system, known as Mara, which is designed for the in-office treatment of heavy menstrual bleeding, specifically menorrhagia. This FDA-approved technology utilizes adaptive vapor ablation to deliver safe and effective endometrial ablation in a simple procedure that takes only minutes. AEGEA Medical aims to expand treatment options for a broader range of patients while ensuring convenience and confidence for physicians performing these office-based procedures. The company was incorporated in 2007 and continues to focus on enhancing patient outcomes in women's healthcare.

Cardeas Pharma is focused on developing an innovative antibiotic formulation that combines two drugs to target highly resistant Gram-negative bacilli, such as Pseudomonas aeruginosa and Acinetobacter baumannii, as well as carbapenem-resistant Enterobacteriaceae. This formulation is designed to treat serious respiratory infections in critical care settings, particularly those caused by antibiotic-resistant organisms. Additionally, it demonstrates efficacy against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and has activity on biofilms. The delivery system utilizes a single-patient use, vibrating-plate nebulizer compatible with all ventilators, which generates small, uniform aerosol droplets that effectively reach the small airways and alveoli. By integrating this novel antibiotic formulation with advanced drug-delivery technology, Cardeas Pharma aims to achieve substantial clinical improvements over current treatment standards.

EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias.

EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in the development of non-invasive drug delivery technologies aimed at treating major eye diseases such as glaucoma, dry eye, and allergies. The company is focused on creating innovative products that can replace traditional eye drops and offer sustained therapeutic effects. Currently, ForSight VISION5 is advancing its lead product, the Helios insert, which is undergoing its second Phase 2 clinical study, reflecting the company's commitment to improving patient care in ophthalmology through effective and patient-friendly solutions.

Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company specializes in a minimally invasive intracanalicular scaffold that alleviates high intraocular pressure by restoring the natural outflow pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its primary focus on glaucoma, Ivantis intends to explore innovative treatments for other ophthalmic diseases as it expands its product offerings. The company also provides a Session Persistence Server to support clinical trials, ensuring data protection for telnet task workers and terminal emulation users across various devices and operating systems.

TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.

Calithera Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule drugs targeting tumor metabolism and immunology for cancer treatment. The company's lead candidate, CB-839, is a glutaminase inhibitor currently in Phase II clinical trials aimed at treating solid tumors. Additionally, Calithera is advancing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology. Other notable projects include CB-280, intended for cystic fibrosis treatment, and CB-708, an inhibitor of CD73. The company has established collaborations, including a license agreement with Mars, Inc. for the development of arginase inhibitors and a clinical trial partnership with Bristol-Myers Squibb to evaluate nivolumab in combination with CB-839. Founded in 2010, Calithera is focused on building a pipeline of innovative cancer therapeutics that address critical pathways necessary for tumor growth and survival.

Karyopharm Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Newton, Massachusetts, specializing in the discovery, development, and commercialization of novel drugs targeting nuclear export mechanisms for the treatment of cancer and other diseases. Its lead drug, XPOVIO (selinexor), is an approved treatment for multiple hematologic malignancies, particularly in patients with heavily pretreated multiple myeloma. The company is advancing several clinical trials for its products, including BOSTON and STORM for multiple myeloma, SADAL for relapsed or refractory diffuse large B-cell lymphoma, and SEAL for liposarcoma. Karyopharm is also exploring treatments for endometrial cancer and glioblastoma multiforme. Additionally, the company has partnerships to investigate low-dose selinexor for hospitalized COVID-19 patients and collaborates with the National Cancer Institute for cancer therapy evaluations. Karyopharm utilizes a proprietary platform to develop small molecule drugs that modulate key cellular pathways involved in cancer and inflammation.

ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization in high-impact eye care companies (ForSight VISION companies). Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves.

ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in the development of non-invasive drug delivery technologies aimed at treating major eye diseases such as glaucoma, dry eye, and allergies. The company is focused on creating innovative products that can replace traditional eye drops and offer sustained therapeutic effects. Currently, ForSight VISION5 is advancing its lead product, the Helios insert, which is undergoing its second Phase 2 clinical study, reflecting the company's commitment to improving patient care in ophthalmology through effective and patient-friendly solutions.

Karyopharm Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Newton, Massachusetts, specializing in the discovery, development, and commercialization of novel drugs targeting nuclear export mechanisms for the treatment of cancer and other diseases. Its lead drug, XPOVIO (selinexor), is an approved treatment for multiple hematologic malignancies, particularly in patients with heavily pretreated multiple myeloma. The company is advancing several clinical trials for its products, including BOSTON and STORM for multiple myeloma, SADAL for relapsed or refractory diffuse large B-cell lymphoma, and SEAL for liposarcoma. Karyopharm is also exploring treatments for endometrial cancer and glioblastoma multiforme. Additionally, the company has partnerships to investigate low-dose selinexor for hospitalized COVID-19 patients and collaborates with the National Cancer Institute for cancer therapy evaluations. Karyopharm utilizes a proprietary platform to develop small molecule drugs that modulate key cellular pathways involved in cancer and inflammation.

Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company specializes in a minimally invasive intracanalicular scaffold that alleviates high intraocular pressure by restoring the natural outflow pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its primary focus on glaucoma, Ivantis intends to explore innovative treatments for other ophthalmic diseases as it expands its product offerings. The company also provides a Session Persistence Server to support clinical trials, ensuring data protection for telnet task workers and terminal emulation users across various devices and operating systems.

Labcyte Inc. is a laboratory instrumentation company based in San Jose, California, specializing in acoustic droplet ejection (ADE) technology for life sciences applications. Established in 2000, Labcyte develops innovative solutions for drug discovery, genomic research, cancer research, and personalized medicine through its precise liquid dispensing technology. This technology utilizes focused acoustic energy to eject nanoliter-scale droplets of fluid, allowing for high accuracy and reduced consumption of materials. Labcyte's product offerings include automation systems, laboratory workstations, and control software aimed at enhancing research efficiency and data reliability. The company operates as a subsidiary of Beckman Coulter, Inc. and maintains additional offices across multiple countries, including Canada, the United Kingdom, and Japan.

Calithera Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule drugs targeting tumor metabolism and immunology for cancer treatment. The company's lead candidate, CB-839, is a glutaminase inhibitor currently in Phase II clinical trials aimed at treating solid tumors. Additionally, Calithera is advancing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology. Other notable projects include CB-280, intended for cystic fibrosis treatment, and CB-708, an inhibitor of CD73. The company has established collaborations, including a license agreement with Mars, Inc. for the development of arginase inhibitors and a clinical trial partnership with Bristol-Myers Squibb to evaluate nivolumab in combination with CB-839. Founded in 2010, Calithera is focused on building a pipeline of innovative cancer therapeutics that address critical pathways necessary for tumor growth and survival.

Tandem Diabetes Care, Inc. is a medical device company headquartered in San Diego, California, which specializes in the design, development, and commercialization of insulin delivery systems for individuals with insulin-dependent diabetes. Its flagship product, the t:slim X2 insulin delivery system, includes a pump, a 300-unit disposable insulin cartridge, and an infusion set. The company offers advanced features such as Basal-IQ Technology and Control-IQ Technology, along with the Tandem Device Updater for software enhancements. Additionally, Tandem provides the t:connect web-based data management application and the Sugarmate mobile app to support diabetes management for users and their caregivers. Tandem Diabetes Care entered the insulin pump market in 2012 and has since expanded its product line, including the recent launch of the smaller Mobi pump and development of a tubeless pump. The majority of the company’s revenue is generated in the United States, with additional sales from other developed countries.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, specializing in the development and commercialization of late-stage medicines for conditions primarily in the iron deficiency, nephrology, and cardio-renal therapeutic areas. The company is known for its product VELTASSA, a potassium binder designed to treat hyperkalemia. Relypsa focuses on discovering and developing non-absorbed polymeric drugs that address cardiovascular and renal diseases, particularly conditions that are often overlooked or undertreated. Established in 2007, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, specializing in the development and commercialization of late-stage medicines for conditions primarily in the iron deficiency, nephrology, and cardio-renal therapeutic areas. The company is known for its product VELTASSA, a potassium binder designed to treat hyperkalemia. Relypsa focuses on discovering and developing non-absorbed polymeric drugs that address cardiovascular and renal diseases, particularly conditions that are often overlooked or undertreated. Established in 2007, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.

Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.

Calithera Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule drugs targeting tumor metabolism and immunology for cancer treatment. The company's lead candidate, CB-839, is a glutaminase inhibitor currently in Phase II clinical trials aimed at treating solid tumors. Additionally, Calithera is advancing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology. Other notable projects include CB-280, intended for cystic fibrosis treatment, and CB-708, an inhibitor of CD73. The company has established collaborations, including a license agreement with Mars, Inc. for the development of arginase inhibitors and a clinical trial partnership with Bristol-Myers Squibb to evaluate nivolumab in combination with CB-839. Founded in 2010, Calithera is focused on building a pipeline of innovative cancer therapeutics that address critical pathways necessary for tumor growth and survival.

Pivot Medical is a privately held medical device company focused on developing and marketing novel technologies for a rapidly growing segment of the orthopedic marketplace. The advancements currently on the market and in development by our company hold great promise for those active persons seeking minimally invasive treatments.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, specializing in the development and commercialization of late-stage medicines for conditions primarily in the iron deficiency, nephrology, and cardio-renal therapeutic areas. The company is known for its product VELTASSA, a potassium binder designed to treat hyperkalemia. Relypsa focuses on discovering and developing non-absorbed polymeric drugs that address cardiovascular and renal diseases, particularly conditions that are often overlooked or undertreated. Established in 2007, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.

AEGEA Medical, Inc. is a medical technology company based in Menlo Park, California, that specializes in innovative treatments for women's health. The company has developed a water vapor ablation system, known as Mara, which is designed for the in-office treatment of heavy menstrual bleeding, specifically menorrhagia. This FDA-approved technology utilizes adaptive vapor ablation to deliver safe and effective endometrial ablation in a simple procedure that takes only minutes. AEGEA Medical aims to expand treatment options for a broader range of patients while ensuring convenience and confidence for physicians performing these office-based procedures. The company was incorporated in 2007 and continues to focus on enhancing patient outcomes in women's healthcare.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias.

ELENZA, Inc. is a medical technology company specializing in the development and commercialization of innovative electro-active AutoFocal intraocular lenses (IOLs) designed to enhance vision for patients undergoing cataract extraction and to address presbyopia. Founded in 2008 and based in Roanoke, Virginia, with an additional office in Zürich, Switzerland, ELENZA's proprietary IOL technology utilizes a unique combination of liquid-crystal chemistry, electricity, and integrated circuitry to create smart optics. These lenses automatically adjust their focusing power electronically, allowing for seamless transitions between near, intermediate, and distance vision. The electro-active lenses are powered by a micro-sized battery with a long rechargeable cycle life, aiming to provide a natural and clear visual experience across various lighting conditions.

NeurAxon, Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase. It has oral products in pipeline addressing acute migraine, neuropathic pain chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. The company was founded in 2004 and is headquartered in Toronto, Canada.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, specializing in the development and commercialization of late-stage medicines for conditions primarily in the iron deficiency, nephrology, and cardio-renal therapeutic areas. The company is known for its product VELTASSA, a potassium binder designed to treat hyperkalemia. Relypsa focuses on discovering and developing non-absorbed polymeric drugs that address cardiovascular and renal diseases, particularly conditions that are often overlooked or undertreated. Established in 2007, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

NeuroVista Corporation is a medical device company pioneering new technologies for the management and treatment of epilepsy, a condition that affects roughly 3 million people in the United States. The defining characteristic of epilepsy is recurrent seizures that strike without warning. Symptoms may range from brief suspension of awareness, to loss of consciousness, to violent convulsions. Unlike other neurological conditions, such as stroke or Alzheimer's disease which tend to develop later in life, epilepsy often affects people in the prime of their lives, with the majority between 15 and 64 years of age.

TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.

BARRX Medical, Inc. specializes in developing endoscopic treatment solutions for Barrett's esophagus, a precancerous condition linked to gastroesophageal reflux disease (GERD). The company offers advanced ablation systems, including HALOFLEX, HALO360, and HALO90, which utilize a balloon-based electrode to deliver a uniform and controlled ablation effect aimed at removing diseased tissue and promoting the regrowth of healthy cells. Clinical studies have demonstrated the effectiveness of these systems, showing high rates of complete eradication of dysplasia and intestinal metaplasia, along with a significant reduction in disease progression and cancer development. The HALO systems have received FDA clearance for use in the United States and hold CE Mark approval for Europe. To date, more than 58,000 procedures have been successfully performed in over 400 hospitals globally. Founded in 2000 and based in Sunnyvale, California, BARRX Medical is a privately-held company committed to addressing chronic gastroenterological diseases.

Calithera Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule drugs targeting tumor metabolism and immunology for cancer treatment. The company's lead candidate, CB-839, is a glutaminase inhibitor currently in Phase II clinical trials aimed at treating solid tumors. Additionally, Calithera is advancing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology. Other notable projects include CB-280, intended for cystic fibrosis treatment, and CB-708, an inhibitor of CD73. The company has established collaborations, including a license agreement with Mars, Inc. for the development of arginase inhibitors and a clinical trial partnership with Bristol-Myers Squibb to evaluate nivolumab in combination with CB-839. Founded in 2010, Calithera is focused on building a pipeline of innovative cancer therapeutics that address critical pathways necessary for tumor growth and survival.

Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).

Breathe Technologies, Inc. is a medical technology company based in Irvine, California, that specializes in developing and manufacturing innovative respiratory therapies for treating respiratory insufficiency diseases. Founded in 2005, the company focuses on creating non-invasive open ventilation systems aimed at helping patients with conditions such as interstitial lung diseases, neuromuscular disorders, and those undergoing lung transplants. Their lightweight, volume-control mechanical ventilators are designed to enhance patient mobility and are suitable for use in various healthcare settings, including general medical units, intensive care, and pulmonary rehabilitation. As a subsidiary of Hill-Rom, Breathe Technologies is committed to providing reliable and accessible solutions that optimize breathing and improve the quality of life for patients both in hospital and home environments.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

Tandem Diabetes Care, Inc. is a medical device company headquartered in San Diego, California, which specializes in the design, development, and commercialization of insulin delivery systems for individuals with insulin-dependent diabetes. Its flagship product, the t:slim X2 insulin delivery system, includes a pump, a 300-unit disposable insulin cartridge, and an infusion set. The company offers advanced features such as Basal-IQ Technology and Control-IQ Technology, along with the Tandem Device Updater for software enhancements. Additionally, Tandem provides the t:connect web-based data management application and the Sugarmate mobile app to support diabetes management for users and their caregivers. Tandem Diabetes Care entered the insulin pump market in 2012 and has since expanded its product line, including the recent launch of the smaller Mobi pump and development of a tubeless pump. The majority of the company’s revenue is generated in the United States, with additional sales from other developed countries.

EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.

BaroSense is committed to develop and commercialize novel anti-obesity products that provide a meaningful contribution to this leading healthcare problem facing the United States today. BaroSense was conceived in order to create a safe, simple, effective, and minimally invasive alternative to the surgical treatment of obesity - an innovative approach to assist those people who need help beyond traditional diets, and who wish to avoid extensive, irreversible surgery.

VytronUS, Inc. specializes in the manufacture and marketing of cardiac medical devices aimed at treating cardiac arrhythmias. Founded in 2006 and located in Sunnyvale, California, the company focuses on leveraging ultrasound energy to enhance the imaging and therapeutic capabilities of its devices. These innovative products allow for precise non-contact energy delivery and facilitate the production of high-resolution maps of cardiac anatomy. By providing physicians with tools that enable visualization, precision, flexibility, and automation, VytronUS aims to improve the treatment of complex arrhythmias.

Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared